DURHAM, N.C., NOVEMBER 14, 2017 — By 2030, it’s estimated that 75 million people will suffer from some form of dementia, with the cost of patient care reaching $2 trillion annually. By far the most common form of dementia is Alzheimer’s disease, the target of 143 drugs now in development.
Premier Research will examine challenges in pursuing these treatments at a live webinar on Tuesday, November 14 (11 a.m. EST / 4 p.m. GMT / 5 p.m. CST). A Vast Unmet Need: Challenges in Alzheimer’s Clinical Trials will consider the difficulties inherent in Alzheimer’s drug research, evidenced by the absence of any new treatment options since the FDA approved memantine in 2003.
The only path to regulatory approval is well-conducted clinical research, but trials often fail due to poorly understood mechanisms of action, insufficient target engagement, and inadequate study design, among other factors. These help account for why Alzheimer’s trials are historically very expensive and inefficient, and why the clinical trial failure rate leads that of all therapeutic areas.
The webinar will review the current global pipeline of Alzheimer’s trials and their geographic locations, describe innovations in trial design, and promote processes that include preclinical patient populations, clinical assessments, and use of biomarkers as trial outcomes.
Register now for this informative hour-long session.
About Premier Research
Premier Research is a leading clinical development service provider that helps highly innovative biotech, specialty pharma, and medical device companies transform breakthrough ideas into reality. The company has a wealth of experience in the execution of global, regional and local clinical development programs with a special focus on addressing unmet needs in areas such as analgesia, dermatology, medical device, neuroscience, oncology, pediatric, and rare disease. Premier Research operates in 84 countries and employs 1,100 professionals, including a strong international network of clinical monitors and project managers, regulatory, data management, statistical, scientific, and medical experts. They are focused on smart study design for advanced medicines that allow life-changing treatments.